Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Anavex Life Sciences Corp. (AVXL) AI Forecast

Our AI analyzed Anavex Life Sciences Corp.. Create a free account to see the 90-day price prediction.

Free account • 30-day free trial

$AVXL Neutral Signal Full forecast available

Anavex Life Sciences Corp. (AVXL) Stock Forecast 2025


Anavex Life Sciences Corp. (AVXL) AI Stock Price Forecast & Investment Analysis

Anavex Life Sciences Corp. Stock Price Chart and Technical Analysis

Loading chart...

Anavex Life Sciences Corp. (AVXL) - Comprehensive Stock Analysis & Investment Research

Deep dive into Anavex Life Sciences Corp.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on May 4, 2026, 6:10 p.m. (UTC)

Anavex Life Sciences Corp. Investment Summary

When evaluating whether Anavex Life Sciences Corp. (AVXL) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Anavex Life Sciences Corp. (AVXL) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $313 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Anavex Life Sciences Corp.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Anavex Life Sciences Corp. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Anavex Life Sciences Corp. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Anavex Life Sciences Corp.

Sign Up Free
Corporate Identity

Anavex Life Sciences Corp. (Stock Symbol: AVXL) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Anavex Life Sciences Corp.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Anavex Life Sciences Corp....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Anavex Life Sciences Corp....

Unlock Full Company Profile

Get complete details about Anavex Life Sciences Corp.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Anavex Life Sciences Corp....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Anavex Life Sciences Corp....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Anavex Life Sciences Corp....

Unlock Financial Analysis

Get complete financial metrics for Anavex Life Sciences Corp.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Anavex Life Sciences Corp.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial

30-day free trial • Cancel anytime

Strategic Market Position

Anavex Life Sciences Corp. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Anavex Life Sciences Corp. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Financial Strength & Leverage

Anavex Life Sciences Corp. (AVXL) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Anavex Life Sciences Corp. stock analysis.

Deep dive into Anavex Life Sciences Corp.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Anavex Life Sciences Corp. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Anavex Life Sciences Corp.:

P/B Ratio 2.47x
Market Cap $313M
EPS $-0.96
Book Value/Share $1.37
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Anavex Life Sciences Corp. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Anavex Life Sciences Corp.: An ROE of -86.0% indicates room for improvement in shareholder value creation.

ROE -86.0%
ROA -81.9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Anavex Life Sciences Corp.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Anavex Life Sciences Corp.:

D/E Ratio 0.05x
Financial Leverage 1.05x
Interest Coverage -6.3x
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Anavex Life Sciences Corp.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Anavex Life Sciences Corp.:

Operating Cash Flow -$53M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Anavex Life Sciences Corp. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Anavex Life Sciences Corp.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Anavex Life Sciences Corp.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Anavex Life Sciences Corp.:

Income Statement
Operating Income -$89M
Net Income -$108M
R&D Expense $37M
Balance Sheet Highlights (% Of Assets)
Cash & Short-term Investments 132%
Total Liabilities 6%
Dividend & Shareholder Information
Shares Outstanding 93M
Growth Metrics (YoY)
EPS Growth -28.4%

Latest Anavex Life Sciences Corp. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Anavex Life Sciences Corp. (AVXL) stock price and investment outlook.

📰 We are currently updating our news feed for Anavex Life Sciences Corp.. Check back soon for the latest market analysis and company updates.

Anavex Life Sciences Corp. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Anavex Life Sciences Corp. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Acumen Pharmaceuticals, Inc. ABOS ██% $172M x 2.4x
Abpro Holdings, Inc. ABP ██% $310K x 0.0x
Abpro Holdings, Inc. ABPO ██% $970K x x
Arcellx, Inc. ACLX ██% $6.73B x 16.7x
Alpha Cognition Inc. ACOG ██% $129M x 2.1x
Adaptimmune Therapeutics Plc ADAP ██% $77M -13.2x -11.8x
Adma Biologics, Inc. ADMA ██% $2.50B 17.0x 5.2x
Adaptive Biotechnologies Corp ADPT ██% $2.19B x 10.0x
Adverum Biotechnologies, Inc. ADVM ██% $95M -1.8x 2.2x
Agenus Inc AGEN ██% $135M 1174.8x x
Agentix Corp. AGTX ██% $1M x x
Aim Immunotech Inc. AIM ██% $4M x x
Aim Immunotech Inc. AIMI ██% $1M x x
Alector, Inc. ALEC ██% $260M x 8.5x
Aligos Therapeutics, Inc. ALGS ██% $38M x 0.7x
Allogene Therapeutics, Inc. ALLO ██% $740M x 2.5x
Alvotech ALVO ██% $1.08B x x
Amgen Inc AMGN ██% $178.00B 22.8x 19.4x
Apogee Therapeutics, Inc. APGE ██% $5.73B x x
Aptose Biosciences Inc. APTOF ██% $4M x x
Argenx Se ARGX ██% $48.49B x x
Armata Pharmaceuticals, Inc. ARMP ██% $326M x x
Artiva Biotherapeutics, Inc. ARTV ██% $267M x 2.4x
Leonabio, Inc. ATHA ██% $23M -0.2x 0.9x
Atara Biotherapeutics, Inc. ATRA ██% $42M 1.3x x
Atyr Pharma Inc ATYR ██% $82M x 1.2x
Aura Biosciences, Inc. AURA ██% $446M x 3.3x
Autolus Therapeutics Plc AUTL ██% $391M x 2.2x
Anavex Life Sciences Corp. AVXL ██% $313M x 2.5x
Bioatla, Inc. BCAB ██% $7M x x
Biocardia, Inc. BCDA ██% $12M x 13.3x
Brainstorm Cell Therapeutics Inc. BCLI ██% $7M x x
Biocryst Pharmaceuticals Inc BCRX ██% $2.34B 8.9x x
Black Diamond Therapeutics, Inc. BDTX ██% $149M 6.6x 1.3x
Beam Therapeutics Inc. BEAM ██% $3.12B x 2.5x
Biogen Inc. BIIB ██% $27.54B 20.1x 1.5x
Biontech Se BNTX ██% $25.14B x x
Cabaletta Bio, Inc. CABA ██% $404M x 3.6x
Candel Therapeutics, Inc. CADL ██% $526M x 10.1x
C4 Therapeutics, Inc. CCCC ██% $322M x 1.3x
Cidara Therapeutics, Inc. CDTX ██% $6.49B -1.0x 15.4x
Creative Medical Technology Holdings, Inc. CELZ ██% $8M x 1.1x
Cero Therapeutics Holdings, Inc. CERO ██% $1M x x
Cullinan Therapeutics, Inc. CGEM ██% $809M x 2.0x
Compugen Ltd CGEN ██% $256M 3.6x 2.5x
Cg Oncology, Inc. CGON ██% $5.45B x 7.2x
Cognition Therapeutics Inc CGTX ██% $114M x 3.3x
Coherus Oncology, Inc. CHRS ██% $270M 1.6x 4.4x
Calidi Biotherapeutics, Inc. CLDI ██% $3M x 0.9x
Cellectis S.A. CLLS ██% $375M x x
Compass Therapeutics, Inc. CMPX ██% $350M x 1.8x
Mosaic Immunoengineering Inc. CPMV ██% $5M x x
Caribou Biosciences, Inc. CRBU ██% $142M -1.5x 1.0x
Cardiff Oncology, Inc. CRDF ██% $117M x 2.6x
Cardiol Therapeutics Inc. CRDL ██% $149M x x
Curis Inc CRIS ██% $24M x 4.3x
Crispr Therapeutics Ag CRSP ██% $4.95B x 2.6x
Champions Oncology, Inc. CSBR ██% $83M x 19.4x
Cel Sci Corp CVM ██% $19M x 1.7x
Dbv Technologies S.A. DBVT ██% $1.18B x 7.0x
Dbv Technologies S.A. DBVTF ██% $10K x 0.0x
Ginkgo Bioworks Holdings, Inc. DNA ██% $632M x 1.2x
Denali Therapeutics Inc. DNLI ██% $2.86B x 2.8x
Precision Biosciences Inc DTIL ██% $175M x 1.9x
Dyadic International Inc DYAI ██% $29M x 23.4x
Editas Medicine, Inc. EDIT ██% $284M x 10.4x
Eloxx Pharmaceuticals, Inc. ELOX ██% $960K x x
Elutia Inc. ELUT ██% $47M 0.9x 1.7x
Engene Therapeutics Inc. ENGN ██% $486M x 1.7x
Entera Bio Ltd. ENTX ██% $60M x 4.6x
Viskase Holdings, Inc. ENZN ██% $5M x x
Estrella Immunopharma, Inc. ESLA ██% $70M x x
Evaxion A/S EVAX ██% $37M x x
Exelixis, Inc. EXEL ██% $11.47B 14.7x 5.3x
Exozymes Inc. EXOZ ██% $82M x 24.1x
Fate Therapeutics Inc FATE ██% $213M x 1.0x
4d Molecular Therapeutics, Inc. FDMT ██% $475M x 0.9x
Fennec Pharmaceuticals Inc. FENC ██% $223M x 6.3x
Finch Therapeutics Group, Inc. FNCH ██% $12M 0.5x 0.9x
Finch Therapeutics Group, Inc. FNCHQ ██% $13M 0.5x 0.9x
Futuretech Ii Acquisition Corp. FTII ██% $52M x x
Futuretech Ii Acquisition Corp. FTIIU ██% $14M x -0.8x
Gilead Sciences, Inc. GILD ██% $163.38B 19.2x 7.2x
Monte Rosa Therapeutics, Inc. GLUE ██% $1.50B x 6.5x
Genenta Science S.P.A. GNTA ██% $17M x 1.4x
Green Planet Bio Engineering Co. Ltd. GPLB ██% $340K x x
Greenland Mines Ltd GRML ██% $63M x 6.3x
Halozyme Therapeutics, Inc. HALO ██% $7.53B 23.8x 154.3x
Humacyte, Inc. HUMA ██% $190M x 61.1x
Immunitybio, Inc. IBRX ██% $7.19B x x
Inhibikase Therapeutics, Inc. IKT ██% $252M x 1.5x
Imagenebio, Inc. IMA ██% $63M x 0.5x
Immunocore Holdings Plc IMCR ██% $1.43B x 3.8x
Immatics N.V. IMTX ██% $1.45B x x
Immunovant, Inc. IMVT ██% $5.51B x 5.6x
In8bio, Inc. INAB ██% $15M x 0.5x
Inhibrx Biosciences, Inc. INBX ██% $873M -6.8x 109.2x
Mink Therapeutics, Inc. INKT ██% $58M x x
Inmune Bio, Inc. INMB ██% $40M x 1.7x
Intensity Therapeutics, Inc. INTS ██% $13M x 1.1x
Iovance Biotherapeutics, Inc. IOVA ██% $1.40B x 2.0x
Century Therapeutics, Inc. IPSC ██% $417M x 2.6x
Invivyd, Inc. IVVD ██% $429M x 1.8x
Jasper Therapeutics, Inc. JSPR ██% $26M x 6.3x
Kalaris Therapeutics, Inc. KLRS ██% $125M x 1.6x
Klotho Neurosciences, Inc. KLTO ██% $56M x 5.7x
Kodiak Sciences Inc. KOD ██% $2.71B x 17.3x
Krystal Biotech, Inc. KRYS ██% $7.96B 35.4x 6.2x
Kymera Therapeutics, Inc. KYMR ██% $6.63B x 4.3x
Kyverna Therapeutics, Inc. KYTX ██% $536M x 2.3x
Ladrx Corp LADX ██% $20K x 0.1x
Lineage Cell Therapeutics, Inc. LCTX ██% $372M x 8.4x
Lenz Therapeutics, Inc. LENZ ██% $278M x 1.0x
Atyr Pharma Inc LIFE ██% $1.17B x 17.4x
Liminatus Pharma, Inc. LIMN ██% $9M x x
Leonabio, Inc. LONA ██% $83M x 3.0x
Lexeo Therapeutics, Inc. LXEO ██% $421M x 1.7x
Maze Therapeutics, Inc. MAZE ██% $1.50B x 4.2x
Mesoblast Ltd MESO ██% $2.03B x x
Meiragtx Holdings Plc MGTX ██% $871M x x
Metagenomi Therapeutics, Inc. MGX ██% $52M x 0.3x
Molecular Partners Ag MOLN ██% $171M x x
Moderna, Inc. MRNA ██% $18.01B x 2.4x
Neurocrine Biosciences Inc NBIX ██% $13.19B 27.6x 4.1x
Nkgen Biotech, Inc. NKGN ██% $2M -0.1x -0.2x
Neumora Therapeutics, Inc. NMRA ██% $425M x 4.1x
Novavax Inc NVAX ██% $1.31B 3.0x x
Ocugen, Inc. OCGN ██% $562M x x
Outlook Therapeutics, Inc. OTLK ██% $32M x x
Palisade Bio, Inc. PALI ██% $334M x 2.6x
Passage Bio, Inc. PASG ██% $16M x 0.8x
Vaxcyte, Inc. PCVX ██% $7.46B x 2.8x
Biomx Inc. PHGE ██% $7M x x
Pluri Inc. PLUR ██% $33M x x
Protalix Biotherapeutics, Inc. PLX ██% $170M x 3.5x
Pharmacyte Biotech, Inc. PMCB ██% $8M x 0.2x
Prime Medicine, Inc. PRME ██% $616M x 5.1x
Prokidney Corp. PROK ██% $583M x x
Pelthos Therapeutics Inc. PTHS ██% $81M x 2.1x
Qiagen N.V. QGEN ██% $7.43B x 2.0x
Quince Therapeutics, Inc. QNCX ██% $22M x 20.5x
Qrons Inc. QRON ██% $150K x x
Replimune Group, Inc. REPL ██% $199M x 1.0x
Repligen Corp RGEN ██% $6.60B 135.0x 3.1x
Regenxbio Inc. RGNX ██% $464M x 4.5x
Relay Therapeutics, Inc. RLAY ██% $2.21B x 3.9x
Revolution Medicines, Inc. RVMD ██% $27.48B x 16.8x
Recursion Pharmaceuticals, Inc. RXRX ██% $1.79B x 1.6x
Sab Biotherapeutics, Inc. SABS ██% $244M 18.4x 1.6x
Sana Biotechnology, Inc. SANA ██% $872M x 5.4x
Scilex Holding Co SCLX ██% $74M x x
Scinai Immunotherapeutics Ltd. SCNI ██% $3M x 0.3x
Sangamo Therapeutics, Inc SGMO ██% $58M x x
Solid Biosciences Inc. SLDB ██% $702M x 3.9x
Silexion Therapeutics Corp SLXN ██% $2M x 0.9x
Senti Biosciences, Inc. SNTI ██% $32M x 5.7x
Scholar Rock Holding Corp SRRK ██% $5.03B x 20.5x
Surrozen, Inc./De SRZN ██% $395M x x
Sutro Biopharma, Inc. STRO ██% $590M x x
Protara Therapeutics, Inc. TARA ██% $285M x 1.5x
Tarsus Pharmaceuticals, Inc. TARS ██% $2.72B x 7.9x
Tc Biopharm (Holdings) Plc TCBPY ██% $10K x 0.0x
Tscan Therapeutics, Inc. TCRX ██% $73M x 0.6x
Bio-Techne Corp TECH ██% $8.58B 105.8x 4.3x
Tectonic Therapeutic, Inc. TECX ██% $545M x 2.2x
Instil Bio, Inc. TIL ██% $54M x 0.5x
Tenaya Therapeutics, Inc. TNYA ██% $166M x 1.4x
Tourmaline Bio, Inc. TRML ██% $1.23B -3.5x 4.8x
Taysha Gene Therapies, Inc. TSHA ██% $1.85B x 7.5x
Titan Pharmaceuticals Inc TTNP ██% $6M -0.5x 2.2x
Tevogen Bio Holdings Inc. TVGN ██% $28M x x
Twist Bioscience Corp TWST ██% $3.50B x 7.7x
Voyager Acquisition Corp./Cayman Islands VACH ██% $433M 48.2x x
Voyager Acquisition Corp./Cayman Islands VACHU ██% $68M 6.7x 0.0x
Valneva Se VALN ██% $451M x x
Vericel Corp VCEL ██% $1.83B 110.7x 5.2x
Vir Biotechnology, Inc. VIR ██% $1.63B x 2.1x
Vivosim Labs, Inc. VIVS ██% $4M x 0.8x
Vor Biopharma Inc. VOR ██% $672M x x
Vaxart, Inc. VXRT ██% $186M 11.4x 2.1x
Voyager Therapeutics, Inc. VYGR ██% $229M x 1.2x
Windtree Therapeutics Inc /De/ WINT ██% $710K x x
X4 Pharmaceuticals, Inc XFOR ██% $382M x 2.1x
Zeo Scientifix, Inc. ZEOX ██% $14M x x
Zivo Bioscience, Inc. ZIVO ██% $15M x x
Zura Bio Ltd ZURA ██% $517M x 5.1x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Anavex Life Sciences Corp. Stock Forecast

How accurate are Anavex Life Sciences Corp. stock predictions?

Our AI model shows a 15% Spearman correlation coefficient for AVXL predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Anavex Life Sciences Corp. stock price forecasts?

Our analysis considers Anavex Life Sciences Corp.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Anavex Life Sciences Corp. a good investment in 2025?

Based on our AI analysis, Anavex Life Sciences Corp. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Anavex Life Sciences Corp. forecasts updated?

Anavex Life Sciences Corp. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Anavex Life Sciences Corp.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...